Quoin Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary

Quoin Pharmaceuticals

14/08/2026 16:23

Quoin Pharmaceuticals Ltd QNRX.OQ reported a quarterly adjusted loss of $1.90​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-6.28.  The mean expectation of four analysts for the quarter was for a loss of $1.61 per share. Wall Street expected results to range from $-1.93 to $-1.07 per share.
Reported revenue was zero​; analysts expected zero. 
Quoin Pharmaceuticals Ltd's reported EPS for the quarter was a loss of $1.90​.
The company reported a quarterly loss of $5.37 million.
Quoin Pharmaceuticals Ltd shares had risen by 25.0% this quarter and lost 58.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 10.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Quoin Pharmaceuticals Ltd is $16.00, about 62.2% above its last closing price of $6.05
This summary was machine generated from LSEG data August 14 at 03:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.61
-1.90
Missed
Mar. 31 2026 
-1.93
-1.77
Beat
Dec. 31 2025 
-3.34
-1.50
Beat
Sep. 30 2025 
-4.98
-6.71
Missed